GlassScriptPhysician profile
Martin J Backman
NPI 1699738385
$10,638.84
in general payments reported to CMS, 2019-2025
50 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $576 · 2021: $1,085 · 2022: $1,862 · 2023: $2,276 · 2024: $2,215 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,160 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,160.04 |
| Education | $161.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,955.43 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,265.63 | 2021-2024 | Austedo Xr, Austedo |
| Abbvie INC. | $961.87 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Neurocrine Biosciences, INC. | $761.52 | 2022-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $760.37 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Biogen, INC. | $678.60 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Supernus Pharmaceuticals, INC. | $494.45 | 2019-2020 | |
| Eisai INC. | $325.32 | 2021-2025 | |
| Sk Life Science, INC. | $307.46 | 2020-2024 | |
| Emd Serono, INC. | $263.83 | 2021-2025 | Mavenclad, Mavenclad |
| Pfizer INC. | $260.54 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $259.47 | 2022-2025 | Ultomiris |
| Genzyme Corporation | $198.29 | 2020-2022 | |
| Livanova USA, INC. | $186.67 | 2019 | |
| Celgene Corporation | $171.73 | 2022-2024 | Zeposia |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Backman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.